

Special Issue

Current and Upcoming Diagnostics and Prognostics in Multiple Myeloma

Message from the Guest Editor

Dear colleagues, The development of diagnostic and prognostic procedures in multiple myeloma is progressing with significant pace, giving deeper and more substantial information for myeloma patients. The genetic constitution of the clonal plasma cells, analyzed from bone marrow, circulating cells and DNA, as well as the increased information from developing radiological and nuclear-medicine methods, will enable more personalized treatment and follow-up in the future. Our methods of follow-up are also advancing, with more sensitive techniques of measuring minimal residual disease (MRD) laying the ground for studies intensifying and de-intensifying treatment according to the response status of the patient. In this Special Issue, we trail the current and future statuses of these topics, showing where we are and where we are going.

Guest Editor

Dr. Fredrik Schjesvold

1. Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway
2. KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway

Deadline for manuscript submissions

closed (28 February 2023)



Hemato

an Open Access Journal
by MDPI

Impact Factor 1.0
CiteScore 2.0



mdpi.com/si/81089

Hemato
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
hemato@mdpi.com

mdpi.com/journal/

hemato





Hemato

an Open Access Journal
by MDPI

Impact Factor 1.0
CiteScore 2.0



[mdpi.com/journal/
hemato](https://mdpi.com/journal/hemato)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Antonino Carbone

Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a
Carattere Scientifico, 33081 Aviano, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO,
and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 33.8 days after
submission; acceptance to publication is undertaken in 2.5
days (median values for papers published in this journal in
the first half of 2025).